Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on November 20, 2019. The report discloses the resignation of a senior executive officer and the terms of the associated separation agreement.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to the executive separation package:
- Base Salary Payment: $519,021 (100% of current annual base salary).
- Target Bonus: Amount equal to the fiscal year 2019 target bonus (final amount contingent on corporate performance goals).
- Sign-on Bonus Waiver: $200,000 (Company waived the obligation for repayment).
Material Changes
The primary material change is the departure of Wladimir Hogenhuis, M.D., Chief Operating Officer. His resignation is effective January 10, 2020, due to personal reasons. A Separation Agreement was executed on November 22, 2019.
Outlook, Risks, and Contingencies
Contingencies: The executive's entitlement to the separation payments is contingent upon not revoking the general release of claims within seven calendar days of executing the agreement. The bonus payment is contingent on the achievement of corporate performance goals.
Management Commentary: The filing states the resignation is due to personal reasons and does not provide further strategic outlook or risk commentary beyond the executive transition.
Key Facts for Investor Verification
- Confirm the effective date of the COO's departure (January 10, 2020) and any interim leadership arrangements.
- Verify the final calculation of the 2019 performance bonus once corporate goals are assessed.
- Review the full Separation Agreement (Exhibit 10.1) for non-compete or non-solicitation clauses not detailed in the summary.
- Assess the impact of the COO departure on ongoing clinical trials or operational milestones.